A New Era in the Management of CML: The Expanded Role of Second-Generation TKIs (Course CML-VC01.01)
Published on May 30, 2012 Video Case Vignette
Faculty: Michael J. Mauro, MD
Medical Writer: Nancy J. Nordenson, MT (ASCP), MFA
Published on May 30, 2012 Video Case Vignette
Faculty: Michael J. Mauro, MD
Medical Writer: Nancy J. Nordenson, MT (ASCP), MFA
Second-generation tyrosine kinase inhibitors (TKI) are good options as initial therapy for newly diagnosed patients with Philadelphia chromosome positive chronic myelogenous leukemia (CML), as well as second-line therapy when tolerability issues develop in response to prior therapy with imatinib. Join Michael J. Mauro, MD, as he follows the course of two newly diagnosed patients who begin therapy and proceed through treatment milestones with re-evaluations of and adjustments to therapy needed along the way.
Michael J. Mauro, MD
- Associate Professor
- Knight Cancer Institute
- Center for Hematologic Malignancies
- Oregon Health and Science University
- Portland, Oregon
Michael Deininger, MD, PhD, has received grant/research support from Bristol-Myers Squibb, Celgene Corporation, and Genzyme, Inc; and is a consultant for Ariad Pharmaceuticals, Inc., Bristol-Myers Squibb, and Novartis Pharmaceuticals Corporation.
Michael J. Mauro, MD, has received grant/research support from Ariad Pharmaceuticals, Inc., Bristol-Myers Squibb, and Novartis Pharmaceuticals Corporation.
Jerald P. Radich, MD, is a consultant for Axis Pharmaceuticals and Novartis Pharmaceuticals Corporation; and received research support for Novartis Pharmaceuticals Corporation.
Moshe Talpaz, MD, has received grant/research support from Ariad Pharmaceuticals, Inc., Bristol-Myers Squibb, Deciphera Pharmaceuticals, InCyte Corp, Millennium Pharmaceuticals Inc, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals, and sanofi-aventis; and has served on advisory boards for Ariad Pharmaceuticals, Inc., Bristol-Myers Squibb, Deciphera Pharmaceuticals, Novartis Pharmaceuticals Corporation, Pfizer, Inc, and sanofi-aventis.
Available for CME/CE:
Physicians
Publish Date: May 30, 2012 Termination Date: May 29, 2013Nurses
Publish Date: May 30, 2012 Termination Date: May 29, 2013Pharmacists
Publish Date: May 30, 2012 Termination Date: May 29, 2013Estimated time for completion of this activity:
CNE: 34.20 minutes
CPE: 30.00 minutes
Target Audience
This activity is designed for hematologists, oncologists, physician assistants, nurses, and pharmacists who specialize in and care for patients with CML.
Activity Goal
The goal of this CME/CE activity is to provide up-to-date information on key issues and management strategies, and real-world patient case-based scenarios that they can utilize in the treatment of patients with CML.
Learning Objective (s)
- Evaluate the role of second-generation tyrosine kinase inhibitors as first-line therapy in patients newly diagnosed with Philadelphia chromosome positive chronic myelogenous leukemia and as second-line therapy in those patients who are intolerant to prior therapy with imatinib.
CME Information: Physicians
Statement of Accreditation
Projects In Knowledge® is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation
Projects In Knowledge® designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CE Information: Nurses
Projects In Knowledge® (PIK) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
Projects In Knowledge is also an approved provider by the California Board of Registered Nursing, Provider Number CEP-15227.
Upon completion of this course, participants will be awarded 0.57 nursing contact hour(s).
CE Information: Pharmacists
Projects In Knowledge® is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.
This program has been planned and implemented in accordance with the ACPE Criteria for Quality and Interpretive Guidelines. This video case vignette is worth up to 0.5 contact hour (0.05 CEU). The ACPE Universal Activity Number assigned to this Knowledge-type activity is 0052-0000-12-1282-H01-P.
Pharmacists should only claim credit commensurate with the extent of their participation in the activity.
CME/CE Instructions
To obtain CME/CE credit:
- Read or listen to each activity carefully.
- Complete/submit each posttest and evaluation.
- Instantly access and print out your certificate.
There is no fee for this activity.
Projects In Knowledge has developed the contract to demonstrate our commitment to providing the highest quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience.
For more information on the contract, click here.
The Disclosure Policy of Projects In Knowledge® requires that presenters comply with the Standards for Commercial Support. All faculty are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed in the course materials.
For complete prescribing information on the products discussed during this CME/CE activity, please see your current Physicians' Desk Reference (PDR).
Michael J. Mauro, MD has received grant/research support from Ariad Pharmaceuticals, Inc., Bristol-Myers Squibb, and Novartis Pharmaceuticals Corporation.
Peer Reviewer has disclosed no significant relationships.
Dorothy Caputo, MA, BSN, RN (lead nurse planner) has no significant relationships to disclose.
Bernadette Marie Makar, MSN, NP-C, APRN-C (nurse planner) has no significant relationships to disclose.
Nancy J. Nordenson, MT (ASCP), MFA - medical writer, has no significant relationships to disclose.
Projects In Knowledge's staff members have no significant relationships to disclose.
Planning Committee
Dale Bixby, MD, PhD has received consulting fees from Ariad Pharmaceuticals, Inc.; has received fees for non-CME services from Bristol-Myers Squibb, Incyte Corporation, and Novartis Pharmaceuticals Corporation; and has conducted contracted research for Ambit Biosciences Inc, Ascenta Therapeutics, Genzyme Corporation, Merck & Co., Inc., Millennium Pharmaceuticals Inc., Novartis Pharmaceuticals Corporation, and sanofi-aventis.
Michael Deininger, MD, PhD has received grant/research support from Bristol-Myers Squibb, Celgene Corporation, and Genzyme, Inc; and is a consultant for Ariad Pharmaceuticals, Inc., Bristol-Myers Squibb, and Novartis Pharmaceuticals Corporation.
Michael J. Mauro, MD has received grant/research support from Ariad Pharmaceuticals, Inc., Bristol-Myers Squibb, and Novartis Pharmaceuticals Corporation.
Jerald P. Radich, MD is a consultant for Axis Pharmaceuticals and Novartis Pharmaceuticals Corporation; and received research support for Novartis Pharmaceuticals Corporation.
Moshe Talpaz, MD has received grant/research support from Ariad Pharmaceuticals, Inc., Bristol-Myers Squibb, Deciphera Pharmaceuticals, InCyte Corp, Millennium Pharmaceuticals Inc, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals, and sanofi-aventis; and has served on advisory boards for Ariad Pharmaceuticals, Inc., Bristol-Myers Squibb, Deciphera Pharmaceuticals, Novartis Pharmaceuticals Corporation, Pfizer, Inc, and sanofi-aventis.
Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process.
The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.
This CME/CE activity is provided solely as an educational service. Specific patient care decisions are the responsibility of the clinician caring for the patient.
Projects In Knowledge is a registered trademark of Projects In Knowledge, Inc.
Available for CME/CE:
Physicians
Publish Date: May 30, 2012 Termination Date: May 29, 2013Nurses
Publish Date: May 30, 2012 Termination Date: May 29, 2013Pharmacists
Publish Date: May 30, 2012 Termination Date: May 29, 2013Estimated time for completion of this activity:
CNE: 34.20 minutes
CPE: 30.00 minutes
Target Audience
This activity is designed for hematologists, oncologists, physician assistants, nurses, and pharmacists who specialize in and care for patients with CML.
Activity Goal
The goal of this CME/CE activity is to provide up-to-date information on key issues and management strategies, and real-world patient case-based scenarios that they can utilize in the treatment of patients with CML.
Learning Objective (s)
- Evaluate the role of second-generation tyrosine kinase inhibitors as first-line therapy in patients newly diagnosed with Philadelphia chromosome positive chronic myelogenous leukemia and as second-line therapy in those patients who are intolerant to prior therapy with imatinib.
CME Information: Physicians
Statement of Accreditation
Projects In Knowledge® is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation
Projects In Knowledge® designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CE Information: Nurses
Projects In Knowledge® (PIK) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
Projects In Knowledge is also an approved provider by the California Board of Registered Nursing, Provider Number CEP-15227.
Upon completion of this course, participants will be awarded 0.57 nursing contact hour(s).
CE Information: Pharmacists
Projects In Knowledge® is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.
This program has been planned and implemented in accordance with the ACPE Criteria for Quality and Interpretive Guidelines. This video case vignette is worth up to 0.5 contact hour (0.05 CEU). The ACPE Universal Activity Number assigned to this Knowledge-type activity is 0052-0000-12-1282-H01-P.
Pharmacists should only claim credit commensurate with the extent of their participation in the activity.
CME/CE Instructions
To obtain CME/CE credit:
- Read or listen to each activity carefully.
- Complete/submit each posttest and evaluation.
- Instantly access and print out your certificate.
There is no fee for this activity.
Projects In Knowledge has developed the contract to demonstrate our commitment to providing the highest quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience.
For more information on the contract, click here.
The Disclosure Policy of Projects In Knowledge® requires that presenters comply with the Standards for Commercial Support. All faculty are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed in the course materials.
For complete prescribing information on the products discussed during this CME/CE activity, please see your current Physicians' Desk Reference (PDR).
Michael J. Mauro, MD has received grant/research support from Ariad Pharmaceuticals, Inc., Bristol-Myers Squibb, and Novartis Pharmaceuticals Corporation.
Peer Reviewer has disclosed no significant relationships.
Dorothy Caputo, MA, BSN, RN (lead nurse planner) has no significant relationships to disclose.
Bernadette Marie Makar, MSN, NP-C, APRN-C (nurse planner) has no significant relationships to disclose.
Nancy J. Nordenson, MT (ASCP), MFA - medical writer, has no significant relationships to disclose.
Projects In Knowledge's staff members have no significant relationships to disclose.
Planning Committee
Dale Bixby, MD, PhD has received consulting fees from Ariad Pharmaceuticals, Inc.; has received fees for non-CME services from Bristol-Myers Squibb, Incyte Corporation, and Novartis Pharmaceuticals Corporation; and has conducted contracted research for Ambit Biosciences Inc, Ascenta Therapeutics, Genzyme Corporation, Merck & Co., Inc., Millennium Pharmaceuticals Inc., Novartis Pharmaceuticals Corporation, and sanofi-aventis.
Michael Deininger, MD, PhD has received grant/research support from Bristol-Myers Squibb, Celgene Corporation, and Genzyme, Inc; and is a consultant for Ariad Pharmaceuticals, Inc., Bristol-Myers Squibb, and Novartis Pharmaceuticals Corporation.
Michael J. Mauro, MD has received grant/research support from Ariad Pharmaceuticals, Inc., Bristol-Myers Squibb, and Novartis Pharmaceuticals Corporation.
Jerald P. Radich, MD is a consultant for Axis Pharmaceuticals and Novartis Pharmaceuticals Corporation; and received research support for Novartis Pharmaceuticals Corporation.
Moshe Talpaz, MD has received grant/research support from Ariad Pharmaceuticals, Inc., Bristol-Myers Squibb, Deciphera Pharmaceuticals, InCyte Corp, Millennium Pharmaceuticals Inc, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals, and sanofi-aventis; and has served on advisory boards for Ariad Pharmaceuticals, Inc., Bristol-Myers Squibb, Deciphera Pharmaceuticals, Novartis Pharmaceuticals Corporation, Pfizer, Inc, and sanofi-aventis.
Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process.
The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.
This CME/CE activity is provided solely as an educational service. Specific patient care decisions are the responsibility of the clinician caring for the patient.
Projects In Knowledge is a registered trademark of Projects In Knowledge, Inc.
Second-generation tyrosine kinase inhibitors (TKI) are good options as initial therapy for newly diagnosed patients with Philadelphia chromosome positive chronic myelogenous leukemia (CML), as well as second-line therapy when tolerability issues develop in response to prior therapy with imatinib. Join Michael J. Mauro, MD, as he follows the course of two newly diagnosed patients who begin therapy and proceed through treatment milestones with re-evaluations of and adjustments to therapy needed along the way.




